MBX MBX Biosciences, Inc.
Nasdaq · SEC CIK 1776111 · EDGAR
- Bought, last 12 months
- $13.06M 4 purchases by 3 insiders
- Sold, last 12 months
- $2.73M 4 sales by 2 insiders
- Filings on record
- 70 since 2024-09-13, latest 2026-08-05 16:57
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| FHMLS X, L.P. | 10% | $12.00M | — |
| Azoulay Salomon | Chief Medical Off | — | $2.72M |
| Hawryluk P. Kent | Pres, CEO, Dir | $798.4K | $17.9K |
| Hoerter Steven L. | Pres, CEO, Dir | $265.0K | — |
| Bartram Richard | CFO | — | — |
| Smither John W | CFO | — | — |
Transactions 55
Purchase Sale Sale after option exercise All abbreviations
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 16:57 | 2026-08-04 | MBX | Azoulay Salomon | Chief Medical Off | S - Sale | $65.77 | -370 | 14.4K | -3% | -$24.3K | |
| D | 2026-08-04 08:51 | 2026-08-03 | MBX | Smither John W | CFO | A - Grant | $0.00 | +28.0K | 28.0K | New | $0 |
| D | 2026-08-04 08:50 | 2026-08-03 | MBX | Hoerter Steven L. | Pres, CEO, Dir | A - Grant | $0.00 | +71.0K | 82.9K | +595% | $0 |
| DMT | 2026-05-11 16:01 | 2026-05-08 | MBX | Azoulay Salomon | Chief Medical Off | M - OptEx | $11.65 | +70.0K | 29.8K | New | +$815.3K |
| DMT | 2026-05-11 16:01 | 2026-05-08 | MBX | Azoulay Salomon | Chief Medical Off | S - Sale+OE | $38.36 | -70.0K | 14.8K | -83% | -$2.69M |
| 2026-05-08 16:02 | 2026-05-06 | MBX | Azoulay Salomon | Chief Medical Off | S - Sale | $29.54 | -231 | 14.8K | -2% | -$6,824 | |
| 2026-05-08 16:00 | 2026-05-06 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | S - Sale | $29.54 | -607 | 727.7K | -0.1% | -$17.9K | |
| D | 2026-05-04 08:01 | 2026-05-01 | MBX | Hoerter Steven L. | Dir | A - Grant | $0.00 | +11.9K | 11.9K | New | $0 |
| I | 2026-03-16 | 2026-03-13 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | P - Purchase | $28.41 | +18.5K | 486.8K | +4% | +$525.6K |
| D | 2026-02-27 | 2026-02-26 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | M - OptEx | $16.00 | +28.8K | 728.3K | +4% | +$460.3K |
| D | 2026-02-03 | 2026-02-02 | MBX | Bartram Richard | CFO | A - Grant | $0.00 | +15.0K | 15.0K | New | $0 |
| D | 2026-02-03 | 2026-02-02 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | A - Grant | $0.00 | +35.2K | 699.5K | +5% | $0 |
| D | 2026-02-03 | 2026-02-02 | MBX | Azoulay Salomon | Chief Medical Off | A - Grant | $0.00 | +15.0K | 15.0K | New | $0 |
| D | 2025-10-28 | 2025-10-24 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | M - OptEx | $3.25 | +182.9K | 664.3K | +38% | +$594.3K |
| I | 2025-10-21 | 2025-10-20 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | P - Purchase | $13.64 | +20.0K | 468.3K | +4% | +$272.8K |
| I | 2025-10-20 | 2025-10-17 | MBX | Hoerter Steven L. | Dir | P - Purchase | $13.25 | +20.0K | 20.0K | New | +$265.0K |
| I | 2025-09-30 | 2025-09-26 | MBX | FHMLS X, L.P. | 10% | P - Purchase | $18.00 | +666.7K | 5.22M | +15% | +$12.00M |
| 2025-04-10 | 2025-04-08 | MBX | Pescovitz Ora H. | Dir | P - Purchase | $5.89 | +7,693 | 24.3K | +46% | +$45.3K | |
| MI | 2025-02-19 | 2025-02-14+ | MBX | OrbiMed Genesis GP LLC | Dir, 10% | P - Purchase | $10.60 | +190.7K | 3.21M | +6% | +$2.02M |
| MI | 2025-02-19 | 2025-02-14+ | MBX | GORDON CARL L | Dir, 10% | P - Purchase | $10.60 | +190.7K | 747.9K | +34% | +$2.02M |
| DI | 2025-02-05 | 2025-02-04 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | P - Purchase | $10.69 | +50.0K | 448.3K | +13% | +$534.5K |
| DMI | 2024-09-17 | 2024-09-16 | MBX | Makhzoumi Mohamad | 10% | C - Cnv Deriv | — | +3.11M | 3.11M | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | Makhzoumi Mohamad | 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |
| DMI | 2024-09-17 | 2024-09-16 | MBX | Behbahani Ali | 10% | C - Cnv Deriv | — | +3.11M | 1.02M | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | Behbahani Ali | 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |
| DI | 2024-09-17 | 2024-09-16 | MBX | Heron Patrick J | Dir, 10% | P - Purchase | $16.00 | +625.0K | 4.55M | +16% | +$10.00M |
| DI | 2024-09-17 | 2024-09-16 | MBX | Heron Patrick J | Dir, 10% | C - Cnv Deriv | — | +3.93M | 3.93M | New | — |
| DMI | 2024-09-17 | 2024-09-16 | MBX | Chang Carmen | 10% | C - Cnv Deriv | — | +3.11M | 3.11M | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | Chang Carmen | 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |
| DMI | 2024-09-17 | 2024-09-16 | MBX | GORDON CARL L | Dir, 10% | P - Purchase | $16.00 | +750.0K | 653.8K | New | +$12.00M |
| DMI | 2024-09-17 | 2024-09-16 | MBX | GORDON CARL L | Dir, 10% | C - Cnv Deriv | — | +3.06M | 403.8K | New | — |
| D | 2024-09-17 | 2024-09-16 | MBX | NEA Partners 17, L.P. | 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |
| DM | 2024-09-17 | 2024-09-16 | MBX | NEA Partners 17, L.P. | 10% | C - Cnv Deriv | — | +3.11M | 1.02M | New | — |
| DMI | 2024-09-17 | 2024-09-16 | MBX | Florence Anthony A. Jr. | 10% | C - Cnv Deriv | — | +3.11M | 3.11M | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | Florence Anthony A. Jr. | 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |
| DMI | 2024-09-17 | 2024-09-16 | MBX | ORBIMED ADVISORS LLC | Dir, 10% | C - Cnv Deriv | — | +3.06M | 403.8K | New | — |
| DMI | 2024-09-17 | 2024-09-16 | MBX | ORBIMED ADVISORS LLC | Dir, 10% | P - Purchase | $16.00 | +750.0K | 653.8K | New | +$12.00M |
| DMI | 2024-09-17 | 2024-09-16 | MBX | Yang Rick | 10% | C - Cnv Deriv | — | +3.11M | 3.11M | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | Yang Rick | 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |
| DM | 2024-09-17 | 2024-09-16 | MBX | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% | C - Cnv Deriv | — | +1.79M | 1.79M | New | — |
| D | 2024-09-17 | 2024-09-16 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | C - Cnv Deriv | — | +283.8K | 481.4K | +144% | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | C - Cnv Deriv | — | +115.9K | 398.3K | +41% | — |
| DMI | 2024-09-17 | 2024-09-16 | MBX | Walker Paul Edward | 10% | C - Cnv Deriv | — | +3.11M | 3.11M | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | Walker Paul Edward | 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |
| DMI | 2024-09-17 | 2024-09-16 | MBX | SANDELL SCOTT D | 10% | C - Cnv Deriv | — | +3.11M | 3.11M | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | SANDELL SCOTT D | 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |
| DI | 2024-09-17 | 2024-09-16 | MBX | BASKETT FOREST | 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |
| DMI | 2024-09-17 | 2024-09-16 | MBX | BASKETT FOREST | 10% | C - Cnv Deriv | — | +3.11M | 3.11M | New | — |
| D | 2024-09-17 | 2024-09-16 | MBX | FHMLS X, L.P. | 10% | C - Cnv Deriv | — | +3.93M | 3.93M | New | — |
| D | 2024-09-17 | 2024-09-16 | MBX | FHMLS X, L.P. | 10% | P - Purchase | $16.00 | +625.0K | 4.55M | +16% | +$10.00M |
| D | 2024-09-17 | 2024-09-16 | MBX | CORNELIUS JAMES M | Dir | C - Cnv Deriv | — | +102.1K | 102.1K | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | Aynechi Tiba | Dir | P - Purchase | $16.00 | +750.0K | 2.14M | +54% | +$12.00M |
| DI | 2024-09-17 | 2024-09-16 | MBX | Aynechi Tiba | Dir | C - Cnv Deriv | — | +1.39M | 1.39M | New | — |
| DMI | 2024-09-17 | 2024-09-16 | MBX | Mathers Edward T | Dir, 10% | C - Cnv Deriv | — | +3.11M | 3.11M | New | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | Mathers Edward T | Dir, 10% | P - Purchase | $16.00 | +500.0K | 3.61M | +16% | +$8.00M |